IL17A and inflammatory bowel disease: However, these new orally available agents will most likely soon be included in the treatment recommendations for axSpA and provide the clinician with options in patients who are not eligible or have contraindications to TNFi or anti-IL-17, such as allergic reactions, congestive heart failure, or concomitant demyelinating disease (TNFi) and concomitant active IBD (anti-IL-17) (85, 86).